Division of Pulmonary and Critical Care Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
Division of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, 3901 Rainbow BLVD, Mail stop #3007, Kansas City, KS, 66160, USA.
Ann Hematol. 2019 Sep;98(9):2187-2195. doi: 10.1007/s00277-019-03746-3. Epub 2019 Jul 4.
Organizing pneumonia (OP) is a poorly understood complication of hematopoietic stem cell transplant (HSCT). We identified 15 patients diagnosed with OP following HSCT and described their clinical course. CT chest findings were remarkable for multifocal infiltrates that were predominantly consolidating or ground glass opacities. Bronchoalveolar lavage (BAL) was performed on 14 patients with five having lymphocytosis (> 25% lymphocytes), three with eosinophilia (> 5% eosinophils), three with neutrophilia (> 30% neutrophils), and three with normal cell counts. Flow cytometry was analyzed on BAL fluid in 13 patients with 11 having a CD4/CD8 of < 0.9. Initial treatment with 0.3-1.0 mg/kg prednisone resulted in improvement in symptoms, in radiographic findings, and in pulmonary function testing for the majority of patients. Six patients had recurrence of OP after completing treatment. Eleven patients had evidence of extra-pulmonary graft-versus-host disease prior to diagnosis of OP, and seven patients were diagnosed with an upper respiratory tract infection (URI) within 8 weeks of OP diagnosis. Most patients respond well to prednisone with significant improvement in pulmonary function, but risk of recurrence is high after cessation of steroid treatment. Risk factors for the development of OP may include prior URI.
机化性肺炎(OP)是造血干细胞移植(HSCT)后一种尚未被充分了解的并发症。我们共诊断了 15 例 HSCT 后发生 OP 的患者,并描述了他们的临床病程。CT 胸部表现为多灶性浸润影,主要为实变或磨玻璃密度影。14 例行支气管肺泡灌洗(BAL),其中 5 例淋巴细胞增多(>25%淋巴细胞),3 例嗜酸性粒细胞增多(>5%嗜酸性粒细胞),3 例中性粒细胞增多(>30%中性粒细胞),3 例细胞计数正常。对 13 例 BAL 液进行流式细胞术分析,其中 11 例 CD4/CD8<0.9。大多数患者接受 0.3-1.0mg/kg 泼尼松初始治疗后症状、影像学和肺功能测试均得到改善。6 例患者在完成治疗后 OP 复发。11 例患者在 OP 诊断前存在肺外移植物抗宿主病证据,7 例患者在 OP 诊断后 8 周内诊断为上呼吸道感染(URI)。大多数患者对泼尼松反应良好,肺功能显著改善,但停止类固醇治疗后复发风险较高。OP 发展的危险因素可能包括先前的 URI。